Target Achievements underlie Partnership Extension

T-cell therapeutics specialists Crescendo Biologics Ltd (Cambridge) and drug developers Takeda Pharmaceutical Company Ltd have expanded their multi-target discovery collaboration after Crescendo achieved its sixth technical milestone.

Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody®-based therapeutics against certain targets selected by the Japanese multi-national, giving Takeda access to a range of its half-life extension Humabodies for use with its two Humabody programmes, previously licensed in November 2018 and July 2019, along with future Humabody programmes developed during the term of the collaboration expansion.

“Crescendo has again demonstrated its ability to deliver differentiated Humabody molecules against specific targets selected by Takeda, on schedule. The expansion of our collaboration, together with the achievement of this sixth milestone, further validates the excellent work being done at Crescendo to progress the next generation of differentiated cancer therapies,” said CEO Theodora Harold.

Loïc Vincent, Head of Takeda’s OncologyDrug Discovery Unit, commented: “Our fruitful collaboration with Crescendo continues to show great progress. We are delighted to expand our work together, drawing on Takeda’s vast oncology drug discovery experience and Crescendo’s expertise in developing optimally constructed Humabody molecules to quickly advance novel therapeutics with transformative treatment potential towards the clinic.”